Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 41 (10), 1100-4

IL28B Is Associated With Response to Chronic Hepatitis C Interferon-Alpha and Ribavirin Therapy

Affiliations

IL28B Is Associated With Response to Chronic Hepatitis C Interferon-Alpha and Ribavirin Therapy

Vijayaprakash Suppiah et al. Nat Genet.

Abstract

Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-alpha (PEG-IFN-alpha) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-alpha/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFNlambda3; rs8099917 combined P = 9.25 x 10(-9), OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-alpha.

Comment in

Similar articles

See all similar articles

Cited by 654 PubMed Central articles

See all "Cited by" articles

References

    1. Nat Immunol. 2003 Jan;4(1):63-8 - PubMed
    1. Genes Immun. 2009 Mar;10(2):125-31 - PubMed
    1. Biometrics. 1999 Dec;55(4):997-1004 - PubMed
    1. PLoS Genet. 2006 Dec;2(12):e190 - PubMed
    1. Nat Genet. 2006 Aug;38(8):904-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback